• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Medtronic updates on $43B Covidien deal financing

Medtronic updates on $43B Covidien deal financing

October 24, 2014 By Brad Perriello

Medtronic updates on $43B Covidien deal financing

Medtronic (NYSE:MDT) said today that it plans to assume some $16 billion in U.S. debt to help pay for its $43 billion acquisition of Covidien (NYSE:COV), slated to close late this year or early in 2015.

The Fridley, Minn.-based medical device company had planned to use about $13.5 billion in overseas cash for the merger, but new U.S. Treasury rules instituted last month prompted it to change the structure of the deal.

In a regulatory filing today, Medtronic said the new debt, at a rate of 4.0% to 4.5%, is expected to be in place before the deal closes. The company is targeting an "A" credit rating on the debt, which would keep it out of junk bond status.

Standard & Poor’s, which has a negative credit watch on Medtronic, reiterated the watch Oct. 3 on news of the new debt financing plan.

"We now expect to lower the corporate credit rating and the issue-level ratings by 2 notches, to ‘A’ and to lower the short-term rating to ‘A-1’, if the transaction is consummated as expected," the ratings agency said.

Standard & Poor’s had said it expects Medtronic’s pro forma adjusted net leverage ratio to be about 2x to 2.2x after the deal. Today Medtronic said its pro forma net debt to EBITDA would be 1.9x at closing and move to 0.7x in fiscal 2018, with pro forma gross debt to EBITDA at 3.7x at closing before moving to 2.7x in fiscal 2018 and to 2.3x beyond that.

In its Oct. 3 release, Standard & Poor’s said the new debt would mean "a modest increase in net leverage (per our calculations), relative to our prior expectations, due to the haircut we apply to cash balances."

Medtronic also said the deal would be neutral to earnings in fiscal 2019, rather than in fiscal 2018 as previously expected, but will be accretive on a cash EPS basis in fiscal 2016 with "significant accretion thereafter." The deal will also lower Medtronic’s overall tax rate by 2%, according to the filing.

Filed Under: News Well, Wall Street Beat Tagged With: Covidien, Medtronic buys Covidien, Standard & Poor's

More recent news

  • Presidio wins FDA IDE for ultra-low frequency neuromod, hires new CFO
  • Epiminder study backs implantable EEG tech
  • Neurent Medical wins FDA nod for next-gen chronic rhinitis treatment
  • Medtronic unveils “MiniMed” as name for soon-to-be separated Diabetes unit
  • Medtronic issues safety notice for Hugo surgical robot console in Europe

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy